澳亚集团(02425)发布公告，于2025年8月5日完成供股发行2.8亿股新股份。 ...

智通财经APP讯，澳亚集团(02425)发布公告，于2025年8月5日完成供股发行2.8亿股新股份。 ...

翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 澳亞集團有限公司 呈交日期： 2025年8月5日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 是 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | | | 證券代號 (如上市) | 02425 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | 已發行股份（不包括庫存股份）變動 | 庫存股份變動 | | | | | | | 事件 | 每股發行/出售價 (註4) | 已發行股份總數 | 佔有關事件前的現有已發 | 已發行股份（不包括庫存股 ...

II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02425 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 700,463,112 | | 0 | | 700,463,112 | | 增加 / 減少 (-) | | | 0 | | 0 | | | | 本月底結存 | | | 700,463,112 | | 0 | | 700,463,112 | 第 2 頁 共 10 頁 v 1.1.1 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2025年7月31日 | 狀態: | 新提交 | | --- | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | | 公司名稱: | 澳亞集團有限公司 ...

Group 1 - The company, 澳亚集团 (02425), announced the acceptance of 370,565,309 shares in its rights issue, which represents approximately 132.26% of the total 280,185,244 shares offered [1] - The rights issue was oversubscribed by 90,380,065 shares, accounting for about 32.26% of the total shares offered [1] - All conditions outlined in the rights issue prospectus have been met, making the rights issue unconditional as of July 28, 2025 [1] Group 2 - The total amount raised from the rights issue is approximately HKD 314 million, before deducting professional fees and other expenses, with a net amount of about HKD 309 million [1]

Group 1 - The company, Australia Asia Group (02425), announced the acceptance of 370,565,309 shares in a rights issue, which represents approximately 132.26% of the total 280,185,244 shares offered [1] - The rights issue was oversubscribed by 90,380,065 shares, accounting for about 32.26% of the total shares offered [1] - All conditions outlined in the rights issue prospectus have been met, making the rights issue unconditional as of July 28, 2025 [1] Group 2 - The total amount raised from the rights issue is approximately HKD 314 million, with a net amount of about HKD 309 million after deducting professional fees and other expenses [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 於本公告內所述之證券並無根據美國證券法或美國任何州或司法權區之法律登記，在未登記或 未獲豁免遵守美國證券法及適用美國州法律之登記規定之情況下，不得在美國境內要約或出 售。現時無意在美國登記本公告內所述之任何部分供股或任何證券，又或在美國進行證券公開 發售。 本公告僅供參考，並不構成收購、購買或認購本公司任何證券的邀請或要約。 AustAsia Group Ltd. 澳亞集團有限公司 * （於新加坡共和國註冊成立的有限公司） （股份代號：02425） 1 (i) 已收到3份暫定配額通知書項下暫定配額之有效接納，總計195,831,419股供 股股份，約佔根據供股提呈的280,185,244股供股股份總數的69.89%；及 (ii) 已收到2份額外申請表格項下額外供股股份之有效申請，總計174,733,890股 供股股份，約佔根據供股提呈的280,185,244股供股股份總數的62.36%。 總計5份有關37 ...

Core Viewpoint - As of July 18, 160 stocks reached their 52-week highs, with notable performances from China New Economy Investment (00080), Aoyuan Group Equity (02905), and Zhong An Holdings Group (08462) showing high growth rates of 288.89%, 55.28%, and 50.00% respectively [1][2]. Summary by Category 52-Week High Performers - China New Economy Investment (00080) closed at 0.440, with a peak price of 0.700, achieving a growth rate of 288.89% [2]. - Aoyuan Group Equity (02905) closed at 0.218, with a peak price of 0.250, achieving a growth rate of 55.28% [2]. - Zhong An Holdings Group (08462) closed at 0.221, with a peak price of 0.228, achieving a growth rate of 50.00% [2]. - Other notable performers include Hualian International (00969) with a growth rate of 40.13% and Zhongke Bio (01237) with a growth rate of 37.25% [2]. Additional High Performers - Wanma Holdings (06928) closed at 0.550 with a growth rate of 30.43% [2]. - Lepu Biopharma-B (02157) closed at 7.940 with a growth rate of 24.54% [2]. - Other stocks with significant growth include ZhiJianYueDong (06860) at 17.14% and China Jindian Group (08281) at 17.12% [2]. 52-Week Low Performers - The document also lists stocks that reached their 52-week lows, with XI Ernan CO-U (09311) showing a decline of 16.10% [6]. - Other notable declines include XI Ernan CO (07311) at -12.62% and Haotian International Construction Investment (01341) at -5.70% [6].

Economic Overview - In 2024, China's GDP growth was 5%, but the economy faced significant challenges, including a decline in consumer confidence and spending, leading to a "consumption downgrade" trend[25]. - The dairy industry in China was among the ten "profit declining industries," with almost all listed dairy companies reporting revenue declines[25]. - The total sales volume of dairy products decreased by approximately 1.5% in 2024, following a 2% decline in 2023[25]. Dairy Production and Pricing - The total raw milk production volume in China decreased by 2.9% to approximately 40.8 million tons, down from 42.0 million tons in 2023[27]. - The national average raw milk price fell from RMB4.4/kg in August 2021 to RMB3.1/kg in December 2024, marking a 30% decrease over more than three years[25]. - The average selling price of raw milk decreased by 17.0%, from RMB4,268/ton to RMB3,541/ton[106]. - The average selling price of raw milk fell to RMB3,541/ton in 2024 from RMB4,268/ton in 2023, while the total sales volume increased to approximately 815,937 tons from 783,028 tons[134][140]. Dairy Industry Challenges - The number of dairy cows in China's 10 major milk production provinces reduced by 6.7% during the first three quarters of 2024[27]. - Approximately 1.2 million dairy cows were eliminated from the dairy industry in 2023 and 2024 combined[27]. - The number of scaled dairy farms in China dropped by 20% from 4,600 in 2022 to 3,700 by the end of 2024[84]. - China imported 2.6 million tons of various dairy products in 2024, representing a decrease of 9.6% year on year[87]. Company Performance - The company recorded a revenue of approximately RMB3,683.8 million for the reporting year, representing a decrease of 6.1% compared to 2023[68]. - Gross profit decreased by 30.7%, from approximately RMB708.5 million to RMB491.0 million, primarily due to a 17.0% decrease in raw milk selling price and a 16.4% decrease in beef cattle selling price[69]. - The company reported a net loss of approximately RMB1,269.3 million, mainly attributable to losses from changes in the fair value of other biological assets amounting to RMB1,260.6 million[69]. - Cash EBITDA for the year was approximately RMB513.3 million, a decrease of 32.6% compared to the previous year[67]. Beef Cattle Market - The demand for high-quality beef, particularly premium products like Wagyu beef, is anticipated to grow significantly[29]. - Beef cattle sales volume increased significantly by 64.5% to 19,415 tons, while the selling price decreased by 16.4%[68]. - The gross loss from the beef cattle business increased significantly to RMB90.0 million in 2024, compared to a gross loss of RMB3.6 million in 2023, primarily due to lower selling prices[155]. Financial Metrics - The basic and diluted loss per share for the Company was RMB 1.81 in 2024, compared to a loss of RMB 0.70 per share in 2023[179]. - The pre-tax loss for the reporting year was RMB 1,250.5 million, compared to RMB 470.0 million in 2023, representing a significant increase in losses[180]. - Net cash flows from operating activities for the reporting year were RMB 813.6 million, significantly higher than RMB 184.0 million in 2023[189]. Investment and Development - The company is focusing on sustainable development and has made continuous investments in research and innovation related to carbon emission reduction[98]. - Research and development expenses amounted to RMB 13.6 million in 2024, compared to nil in 2023, primarily generated by the feed mill[172]. Debt and Financing - As of December 31, 2024, the total secured bank loans amount to RMB 3,498,392,000, an increase from RMB 3,400,323,000 as of December 31, 2023, reflecting a growth of approximately 2.9%[200]. - The effective interest rate for current secured bank loans ranges from 3.90% to 4.80% in 2024, compared to 4.00% to 4.80% in 2023[200]. - The overall financial strategy appears focused on managing interest rates and loan maturities effectively to optimize capital structure[200].

Core Insights - The company reported a revenue of 3.684 billion yuan for the year ending December 31, 2024, representing a year-on-year decrease of 6.1% [2] - Gross profit was 491 million yuan, down 30.7% year-on-year, while net loss increased to 1.269 billion yuan, a rise of 159.7% [2] - The increase in losses is attributed to changes in the fair value of biological assets, but the company emphasizes that these losses are not cash losses and suggests focusing on gross profit and CASH EBITDA as more relevant performance indicators [2] Financial Performance - Revenue: 3.684 billion yuan, down 6.1% year-on-year [2] - Gross Profit: 491 million yuan, down 30.7% year-on-year [2] - Net Loss: 1.269 billion yuan, up 159.7% year-on-year [2] Operational Strategy - The company aims to reduce costs and improve efficiency in its dairy farm operations by increasing milk production per cow and lowering feed costs [2] - The company has effectively controlled raw milk production by increasing the elimination rate of milking cows and selling excess young cattle, leading to over 30% growth in finished milk sales [3] - In the beef business, the company is adjusting its cattle structure and launching its own beef brand to enhance profitability [3] Market Outlook - The company believes the dairy industry has passed its lowest point in the current cycle, with a noticeable reduction in supply-side capacity, and anticipates that the current cycle will end in the second half of this year [2] - The company expresses confidence in quickly restoring profitability and gaining a competitive edge once market conditions improve [3]